ReviewNature reviews. Urology2011
Active surveillance for low-risk prostate cancer: an update.
Review in Nature reviews. Urology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 72 citations in OpenAlex.
- Trial
- Research progress of MUC1 in genitourinary cancers.Cellular & molecular biology letters · 2024Review
- Developing a Multimodal Model for Detecting Higher-Grade Prostate Cancer Using Biomarkers and Risk Factors.BioMed research international · 2022Article
- Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.BMC cancer · 2021Article
- Psychiatric Disorders and Cardiovascular Diseases During the Diagnostic Workup of Suspected Prostate Cancer.JNCI cancer spectrum · 2021Article
- Clinical utility of current biomarkers for prostate cancer detection.Investigative and clinical urology · 2021Review
- Review
- Landmarks in prostate cancer.Nature reviews. Urology · 2018Review
- Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital?Clinical genitourinary cancer · 2018Article
- Nurse-led active surveillance for prostate cancer is safe, effective and associated with high rates of patient satisfaction-results of an audit in the East of England.Ecancermedicalscience · 2018Article
- Updated clinical results of active surveillance of very-low-risk prostate cancer in Korean men: 8 years of follow-up.Investigative and clinical urology · 2017Article
- The Use of Biomarkers in Prostate Cancer Screening and Treatment.Reviews in urology · 2017Review
- PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.European radiology · 2016Article
- Assessment of Prostate Cancer Aggressiveness by Use of the Combination of Quantitative DWI and Dynamic Contrast-Enhanced MRI.AJR. American journal of roentgenology · 2016Article
- Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN.World journal of urology · 2015Article
- Using routinely collected data to stratify prostate cancer patients into phases of care in the United Kingdom: implications for resource allocation and the cancer survivorship programme.British journal of cancer · 2015Article
- Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate Cancer.BioMed research international · 2015Review
- Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer.European radiology · 2014Article
- Looking forward, looking back-10 years in urology.Nature reviews. Urology · 2014Review
- A single centre experience of active surveillance as management strategy for low-risk prostate cancer in Ireland.Irish journal of medical science · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Active surveillance is now an accepted management strategy for men with low-risk localized prostate cancer, in recognition of the knowledge that the majority of men with such cancers are likely to die from other causes. The most obvious benefit of active surveillance is the reduction of morbidity associated with surgery by delaying or avoiding radical gland therapy. Other advantages include lower overall costs to the health-care system and potentially a better quality of life. These advantages should be balanced against the risks of delayed therapy, the most considerable of which being development of more-aggressive disease. Appropriate selection criteria and the definition of triggers for intervention with radical therapy are critical components of an active surveillance protocol. The ability to accurately identify and cure the men whose cancers will progress using clinical, biopsy and imaging data is yet to be resolved, as is the psychological burden of living with an untreated cancer. The benefit of 5α-reductase inhibitors as secondary chemoprevention in men on active surveillance is a new avenue of research. Focal therapy, which has the similar aim of reducing morbidity while maintaining oncological control, is an emerging competitor for active surveillance. Nevertheless, active surveillance is an appealing management option for selected men with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.